Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 5/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | AR | P10275 | 1/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.32 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.32 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.31 |
| ▸ | MAOB | P27338 | 1/20 | 0.31 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.31 |
| ▸ | BCHE | P06276 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7987458 | 0.72 | AR (0.42) | ALDH1A1ARPTPN2PTPN1KDM4E | |
| SCHEMBL5667289 | 0.69 | AOC3 (0.36) | ALDH1A1HRH3KDM4EMAPTLOXL2 | |
| SCHEMBL7775103 | 0.69 | AR (0.42) | ALDH1A1ARHRH3KDM4EMAPT | |
| SCHEMBL7207164 | 0.69 | LOXL2 (0.50) | ALDH1A1ARHRH3KDM4EMAPT | |
| SCHEMBL4273420 | 0.69 | MAPT (0.45) | ALDH1A1ARKDM4EMAPTLOXL2 | |
| SCHEMBL28975117 | 0.68 | GABRP (0.48) | ALDH1A1ARKDM4EMAPTLOXL2 | |
| SCHEMBL4265909 | 0.68 | DRD2 (0.46) | ALDH1A1ARKDM4EMAPTLOXL2 | |
| SCHEMBL5557187 | 0.68 | LOXL2 (0.49) | ALDH1A1ARHRH3KDM4EMAPT | |
| SCHEMBL31370881 | 0.68 | KDM4E (0.41) | AKR1C3ALDH1A1ARKDM4EMAPT | |
| SCHEMBL7331250 | 0.68 | AR (0.41) | ALDH1A1ARHRH3KDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1390364-B1 | ARYL-8-AZABICYCLO 3.2.1]OCTANES FOR THE TREATMENT OF DEPRESSION | WYETH CORP (US) | 2004-09-29 | — | — | EP | disclosed |
| EP-1390364-A1 | ARYL-8-AZABICYCLO 3.2.1]OCTANES FOR THE TREATMENT OF DEPRESSION | Wyeth (US) | 2004-02-25 | — | — | EP | disclosed |
| US-6632824-B2 | Have the ability to act at the 5-HT transporter. | WYETH | 2003-10-14 | — | — | US | disclosed |
| US-20030032645-A1 | Aryl-8-azabicyclo [3.2.1] octanes for the treatment of depression | WYETH | 2003-02-13 | — | — | US | disclosed |
| WO-2002096906-A1 | ARYL-8-AZABICYCLO[3.2.1]OCTANES FOR THE TREATMENT OF DEPRESSION | WYETH (US) | 2002-12-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030032645-A1 | Aryl-8-azabicyclo [3.2.1] octanes for the treatment of depression | HTR1A, HTR1D, HTR2C | AKR1C3 273/4885ALDH1A1 124/4885AR 66/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.